Chen Ning, Li Qifu, Zhang Yun, Zhou Muke, Zhou Dong, He Li
Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.
Cochrane Database Syst Rev. 2011 Mar 16(3):CD007795. doi: 10.1002/14651858.CD007795.pub2.
Herpes zoster virus vaccine was recommended for the prevention of herpes zoster and its sequelae by the Advisory Committee on Immunization Practices (ACIP) in 2006. To date the efficacy and safety of vaccination for preventing the most common complication of zoster, postherpetic neuralgia, has not been systematically reviewed.
To assess the efficacy and safety of vaccination in preventing postherpetic neuralgia.
We searched MEDLINE (January 1966 to December 2010), EMBASE (January 1980 to January 2011), LILACS (January 1982 to December 2010), the Cochrane Neuromuscular Disease (NMD) Group Specialized Register (10 January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (10 January 2010 in the Cochrane Library, Issue 4, 2010) and the Chinese Biomedical Retrieval System (January 1978 to December 2010). We also checked the references of published studies to identify additional trials.
We included all randomised controlled trials comparing varicella zoster virus vaccination with placebo, no vaccination or another intervention, irrespective of publication status or language.
Two authors independently assessed trial quality, then extracted and analysed data from the trials which met the inclusion criteria. We collected adverse effects information from the trials.
One trial, which involved 38,546 subjects and compared vaccination with placebo, met our inclusion criteria. This included study was of high quality. However, its participants were all aged 60 years or more and most of them were white, which may mean that its findings are not applicable to all populations. The vaccine was effective in decreasing the incidence of herpes zoster, but there was no evidence that it had efficacy in reducing the incidence of postherpetic neuralgia beyond its effect on the incidence of herpes zoster. Adverse events at the injection site were more common among vaccine recipients than placebo recipients, but they were mild and resolved in a few days. Serious adverse events were rare.
AUTHORS' CONCLUSIONS: There is insufficient direct evidence from specialised trials to prove the efficacy of vaccine for preventing postherpetic neuralgia beyond its effect on reducing herpes zoster, although vaccination may be efficacious and safe for preventing herpes zoster and thus reduce the incidence of postherpetic neuralgia in adults aged 60 years or older.
2006年，免疫实践咨询委员会（ACIP）推荐使用带状疱疹病毒疫苗来预防带状疱疹及其后遗症。迄今为止，针对预防带状疱疹最常见的并发症——带状疱疹后神经痛的疫苗接种的有效性和安全性尚未得到系统评价。
评估接种疫苗预防带状疱疹后神经痛的有效性和安全性。
我们检索了MEDLINE（1966年1月至2010年12月）、EMBASE（1980年1月至2011年1月）、LILACS（1982年1月至2010年12月）、Cochrane神经肌肉疾病（NMD）小组专业注册库（2010年1月10日）、Cochrane对照试验中央注册库（CENTRAL）（2010年第4期Cochrane图书馆，2010年1月10日）以及中国生物医学文献数据库（1978年1月至
